Group 1 - The core point of the news is that Haofan Bio experienced a decline of 5.02% in its stock price, closing at 54.50 yuan per share, with a trading volume of 1.07 billion yuan and a turnover rate of 4.60%, resulting in a total market capitalization of 58.86 billion yuan [1] - Haofan Bio, established on December 2, 2003, and listed on July 12, 2023, is located in Suzhou, Jiangsu Province, and specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] - The revenue composition of Haofan Bio's main business includes peptide synthesis reagents at 81.89%, general molecular building blocks at 10.99%, protein reagents at 6.11%, and other products at 1.01% [1] Group 2 - Among the top circulating shareholders of Haofan Bio, a fund under Huatai-PineBridge holds a significant position, with the Huatai-PineBridge Healthcare Mixed Fund (470006) increasing its holdings by 264,300 shares to a total of 866,800 shares, representing 2.06% of the circulating shares [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion yuan, achieving a year-to-date return of 10.53% and a one-year return of 37.91% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a tenure of 11 years and 33 days, with the fund's total asset scale at 8.093 billion yuan [3]
昊帆生物股价跌5.02%，汇添富基金旗下1只基金位居十大流通股东，持有86.68万股浮亏损失249.63万元